

Simon Kariuki

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11191683/simon-kariuki-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27
papers

3,003
citations

14
h-index

27
g-index

27
ext. papers

3,612
ext. citations

17.6
avg, IF

3.37
L-index

#	Paper	IF	Citations
27	First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. <i>New England Journal of Medicine</i> , 2011 , 365, 1863-75	59.2	626
26	A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. <i>New England Journal of Medicine</i> , 2012 , 367, 2284-95	59.2	514
25	Protective effects of the sickle cell gene against malaria morbidity and mortality. <i>Lancet, The</i> , 2002 , 359, 1311-2	40	442
24	National and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010. <i>The Lancet Global Health</i> , 2013 , 1, e26-36	13.6	404
23	Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. <i>New England Journal of Medicine</i> , 2015 , 373, 2025-2037	59.2	225
22	Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014 , 91, 833-843	3.2	167
21	A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. <i>Lancet, The</i> , 2002 , 360, 1468-75	40	158
20	Estimates of burden and consequences of infants born small for gestational age in low and middle income countries with INTERGROWTH-21 standard: analysis of CHERG datasets. <i>BMJ, The</i> , 2017 , 358, j3677	5.9	145
19	Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, randomised, controlled, superiority trial. <i>Lancet</i> , 2015 , 386, 2507-16	40	127
18	Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy. <i>Nature Communications</i> , 2019 , 10, 2174	17.4	63
17	Malaria, malnutrition, and birthweight: A meta-analysis using individual participant data. <i>PLoS Medicine</i> , 2017 , 14, e1002373	11.6	25
16	In Vitro and Molecular Surveillance for Antimalarial Drug Resistance in Plasmodium falciparum Parasites in Western Kenya Reveals Sustained Artemisinin Sensitivity and Increased Chloroquine Sensitivity. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 7540-7	5.9	22
15	Polymorphisms in genes of interleukin 12 and its receptors and their association with protection against severe malarial anaemia in children in western Kenya. <i>Malaria Journal</i> , 2010 , 9, 87	3.6	21
14	User and Provider Acceptability of Intermittent Screening and Treatment and Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine to Prevent Malaria in Pregnancy in Western Kenya. <i>PLoS ONE</i> , 2016 , 11, e0150259	3.7	19
13	Malaria Chemoprevention in the Postdischarge Management of Severe Anemia. <i>New England Journal of Medicine</i> , 2020 , 383, 2242-2254	59.2	9
12	Modelling the incremental benefit of introducing malaria screening strategies to antenatal care in Africa. <i>Nature Communications</i> , 2020 , 11, 3799	17.4	9
11	Malaria chemoprevention with monthly dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: study protocol for a multi-centre, two-arm, randomised, placebo-controlled, superiority trial. <i>Trials</i> , 2018 , 19, 610	2.8	8

10	Assessment of molecular markers of anti-malarial drug resistance among children participating in a therapeutic efficacy study in western Kenya. <i>Malaria Journal</i> , 2020 , 19, 291	3.6	4
9	Maternal Malaria and Malnutrition (M3) initiative, a pooled birth cohort of 13 pregnancy studies in Africa and the Western Pacific. <i>BMJ Open</i> , 2016 , 6, e012697	3	4
8	Counter-Selection of Antimalarial Resistance Polymorphisms by Intermittent Preventive Treatment in Pregnancy. <i>Journal of Infectious Diseases</i> , 2020 , 221, 293-303	7	3
7	Knowledge and Adherence to the National Guidelines for Malaria Diagnosis in Pregnancy among Health-Care Providers and Drug-Outlet Dispensers in Rural Western Kenya. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018 , 98, 1367-1373	3.2	2
6	Intermittent screening and treatment with dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy: implementation feasibility in a routine healthcare system setting in western Kenya. <i>Malaria Journal</i> , 2020 , 19, 433	3.6	2
5	Piperaquine Pharmacokinetics during Intermittent Preventive Treatment for Malaria in Pregnancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	2
4	Intermittent screening and treatment with artemisinin-combination therapy versus intermittent preventive treatment with sulphadoxine-pyrimethamine for malaria in pregnancy: a systematic review and individual participant data meta-analysis of randomised clinical trials. <i>EClinicalMedicine</i> , 2021 , 41, 101160	11.3	1
3	Healthcare provider and pregnant women's perspectives on the implementation of intermittent screening and treatment with dihydroartemisinin-piperaquine for malaria in pregnancy in western Kenya: a qualitative study. <i>Malaria Journal</i> , 2021 , 20, 291	3.6	1
2	Cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine for malaria during pregnancy: an analysis using efficacy results from Uganda and Kenya, and pooled data. <i>The Lancet Global Health</i> , 2020 , 8, e1512-e1523	13.6	0
1	Adoption of evidence-based global policies at the national level: intermittent preventive treatment for malaria in pregnancy and first trimester treatment in Kenya, Malawi, Mali and The Gambia. <i>Health Policy and Planning</i> , 2021 , 35, 1364-1375	3.4	0